Cell Cycle-Dependent Variation of a CD133 Epitope in Human Embryonic Stem Cell, Colon Cancer, and Melanoma Cell Lines

Tumor Development Program, Cancer Research Center, Burnham Institute for Medical Research, La Jolla, California 92035, USA.
Cancer Research (Impact Factor: 9.33). 11/2008; 68(19):7882-6. DOI: 10.1158/0008-5472.CAN-08-0723
Source: PubMed


CD133 (Prominin1) is a pentaspan transmembrane glycoprotein expressed in several stem cell populations and cancers. Reactivity with an antibody (AC133) to a glycoslyated form of CD133 has been widely used for the enrichment of cells with tumor-initiating activity in xenograph transplantation assays. We have found by fluorescence-activated cell sorting that increased AC133 reactivity in human embryonic stem cells, colon cancer, and melanoma cells is correlated with increased DNA content and, reciprocally, that the least reactive cells are in the G(1)-G(0) portion of the cell cycle. Continued cultivation of cells sorted on the basis of high and low AC133 reactivity results in a normalization of the cell reactivity profiles, indicating that cells with low AC133 reactivity can generate highly reactive cells as they resume proliferation. The association of AC133 with actively cycling cells may contribute to the basis for enrichment for tumor-initiating activity.

Download full-text


Available from: Robert Glen Oshima
  • Source
    • "Some research have shown that the necessity of β-Catenin for self-renewal of both normal hematopoietic stem cells and Table1. Cancer stem marker and their distribution Marker Tumor type Marker Tumor type CD133 Brain[85] Prostate [86] Pancreas [ 87] Melanoma [88] Colon [88] Liver [89] Lung [19] Ovary [90] ALDH Breast [91] Lung [92] Head and neck [25] Colon [93] Liver [17] Pancreas [94] Gastric [95] Prostate [96] CD44 Colon [97] Breast [8] Prostate [13] Pancreatic [98] ABCB5 Melanoma [99] ABCG2 Pancreas [100] Lung [101] Limbal epithelium [102] Brain [103] prostate [104] Liver [105] Ovarian [106] Retinoblastoma [107] CD90 T-acute lymphoblastic leukemia [108] Gliomas [109] Liver [110] New therapies to target cancer stem cells 344 Am J Cancer Res 2012;2(3):340-356 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer stem cells (CSCs) have been defined as cells within tumor that possess the capacity to self-renew and to cause the heterogeneous lineages of cancer cells that comprise the tumor. They have been identified in blood, breast, brain, colon, melanoma, pancreatic, prostate, ovarian, lung cancers and so on. It is often considered to be associated with chemo-resistance and radio-resistance that lead to the failure of traditional therapies. Most therapies are directed at the fast growing tumor mass but not the slow dividing cancer stem cells. Eradicating cancer stem cells, the root of cancer origin and recurrence, has been thought as a promising approach to improve cancer survival or even to cure cancer patients. Understanding the characteristics of cancer stem cells will help to develop novel therapies to eliminate the initiating cancer stem cell, and the relevant patents on the cancer stem cell and cancer therapy by cancer stem cells will be discussed.
    Preview · Article · Jun 2012 · American Journal of Cancer Research
  • Source
    • "This may be associated with the higher histological grading of GBM, thus supporting studies that suggest CD133 expression can be used as a prognostic factor [3] though CD133 did not achieve prognostic significance in our study. It is possible that not all of the CD133+ cells counted will have been glioma CSC’s with positive staining also depending upon the oxygen concentration and expression of the glycosylated AC133 epitope at different stages of the cell cycle [5, 24, 32]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Paediatric high grade glioma (pHGG) (World Health Organisation astrocytoma grades III and IV) remains poor prognosis tumours, with a median survival of only 15 months following diagnosis. Current investigation of anti-angiogenic strategies has focused on adult glioblastoma multiforme (GBM) with phase III trials targeting vascular endothelial growth factor continuing. In this study we investigated whether the degree of vascularity correlated with prognosis in a large cohort of pHGG (n = 150) and whether different vessel markers carried different prognostic value. We found that CD105 (endoglin) had a strongly significant association with poor prognosis on multivariate analysis (p = <0.001). Supervised hierarchical clustering of genome wide gene expression data identified 13 genes associated with differential degrees of vascularity in the cohort. The novel angiogenesis-associated genes identified in this analysis (including MIPOL-1 and ENPP5) were validated by realtime polymerase chain reaction. We also demonstrate that CD105 positive blood vessels associate with CD133 positive tumour cells and that a proportion of CD105 positive vessel cells demonstrates co-positivity for CD133, suggesting that the recently described phenomenon of vasculogenic mimicry occurs in pHGG. Together, the data suggest that targeting angiogenesis, and in particular CD105, is a valid therapeutic strategy for pHGG. Electronic supplementary material The online version of this article (doi:10.1007/s00401-012-0952-1) contains supplementary material, which is available to authorized users.
    Full-text · Article · Feb 2012 · Acta Neuropathologica
  • Source
    • "A number of important regulators and pathways have been implicated in CSC biology and CD133 expression: mTOR, Wnt/β-catenin [42], PI3K-AKT [8, 13], reactive oxygen species-HIF1a pathway [43], Oct4 [9], and CXCR4 [35, 37]. Similar to embryonic stem cells, CD133+ colon cancer cells or melanoma expression are mostly found in the G1/G0 portion of the cell cycle [36]. CD133 expression is due to the lack of CpG island methylation [44, 45]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: CD133, a member of the prominin family, is found in a variety of tissues with at least three variants. The function of CD133 is not well understood, but its expression is subject to changes in the microenvironment cues including bioenergetic stress. Knockout of CD133 does not affect renewal, but mammary gland branching. A point mutation of CD133 (R733C) leads to retinal disorder. CD133 is found in embryonic stem cells, normal tissue stem cells, stem cell niches, and circulating endothelial progenitors as well as cancer stem cells. Maintenance of stemness in cancer may be attributable to asymmetric cell division in association with a set of embryonic expression signatures in CD133+ tumor cells. CD133 could enrich cancer stem cells, which are associated with chemo- and radiation resistance phenotype. High CD133 is associated with poor survival in a variety of solid tumors, including lung, colon, prostate, etc. Monitoring CD133+ cells in peripheral blood, and targeting CD133 in cancer, may further predict and improve the clinical outcomes.
    Full-text · Article · Dec 2011 · Current Colorectal Cancer Reports
Show more